McDermott Will & Emery advised The Clermont Group as lead investor in the Series A financing of PostEra Inc., a Boston-based biotechnology company specializing in machine learning for preclinical drug discovery. PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform.
The Clermont Group, an international business group headquartered in Singapore, led the Series A financing with participation from Breyer Capital, Lifeforce Capital and I2BF, alongside existing investors including Metaplanet, HOF Capital, Ace & Company and R. Martin Chavez.
The Clermont Group is an international business group headquartered in Singapore. Founded in 1986 by New Zealand-born entrepreneur Mr. Richard F. Chandler, the Clermont Group builds businesses in healthcare, financial services and aerospace.
PostEra was founded in 2019 and its technology is built on pioneering academic research done by its founding scientists. PostEra’s technology addresses some of the key challenges in drug discovery R&D by integrating molecular design with chemical synthesis. PostEra advances small molecule programs through partnerships with biopharma, working on its own internal pipeline, and also offering some of its synthesis technology via its Manifold web platform. PostEra also launched and now helps lead the world’s largest open-science drug discovery effort; COVID Moonshot.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.